Coca-Cola Consolidated, Inc. (NASDAQ: COKE) — A Capped Franchise at an Uncapped Multiple

Independent fundamental research note. Report date: 2026-06-14. All per-share figures are post the 10-for-1 split effective May 2025 unless noted.

⚡ Claude’s Take

This block is the author’s own subjective opinion and general information only — not investment advice. The detailed analysis that follows takes no position and names no price target.

Verdict: HOLD / accumulate only on weakness. A genuinely great business — at a price that already pays for the greatness. Directional zone: I’d treat ~$140–165 (≈10–11.5x EV/EBITDA, ~17–19x normalized earnings — roughly where the stock traded in late-2024/early-2025) as the accumulate-on-weakness band, and the current ~$188 (≈14x EV/EBITDA, P/S at the 97th percentile of its own ten-year history) as a place to hold quality, not to initiate. Conviction: medium.

Coca-Cola Consolidated is the rare bottler that earns a franchisor-like return on capital: operating margin doubled from 6.3% (2020) to 13.2% (2025), ROIC sits near 25% — roughly double Coca-Cola FEMSA’s and Coca-Cola Europacific Partners’ — and the business throws off ~$620M of free cash flow on ~4% of revenue in capex. That is real, and it is the product of the 2017 territory build-out finally maturing: automated distribution centers, the densest direct-store-delivery network in its 14-state footprint, and a richer still/energy/protein mix. The market has correctly identified a higher-quality company than the sleepy bottler of a decade ago, and re-rated it from ~7x to ~14x EV/EBITDA — a near-7x stock in five years. The problem is that the re-rating is now the thesis. Two structural facts cap the upside the multiple is extrapolating: (1) incidence-based concentrate pricing means The Coca-Cola Company automatically claws back a slice of every retail price increase COKE achieves — the pricing power in this system lives at KO, by design; and (2) the recent margin surge was bought largely with price on flat-to-negative volume (FY24 volume −0.6%, FY25 +0.3%), the post-COVID inflation lever, not durable unit growth. Q1’26 is the tell: volume finally inflected (+6.4%) but gross margin compressed ~70bps as aluminum tariffs (~$35M) and a new front-line wage outran pricing. The growth mix is flipping from high-margin price to lower-margin volume exactly as costs bite.

The framing is quality-compounder-at-a-price, not momentum and not a falling knife — this is a low-beta (β≈0.5), defensively-loaded name whose 12-month momentum factor has been neutralized after a +72% year, now in a modest ~12% pullback. The capital allocation is a genuine positive (the November 2025 buyout of KO’s entire 18.8M-share stake at ~$127 was clean and accretive, leaving prudent ~2x net leverage), and a Harrison-family steward with 78% of the vote is unlikely to do anything reckless. But at ~14x EBITDA, ~0.5% yield, and negative book equity, you are underwriting continued margin expansion in a business engineered so its franchisor keeps the pricing power. What flips me bullish: evidence that volume-led growth can hold gross margin near 40% through a full cost cycle (i.e., the structural half of the margin story is winning). What flips me bearish: two or three quarters of incidence-pricing claw-back and input inflation compressing operating margin back toward 11%, with the multiple de-rating on it. Own it lower; admire it here.

1. Executive Summary

Coca-Cola Consolidated, Inc. (“COKE,” “Consolidated,” or “the Company”) is the largest Coca-Cola bottler in the United States, distributing The Coca-Cola Company’s (“KO”) sparkling and still beverages — plus partner brands (Dr Pepper, Monster, BODYARMOR, fairlife) — across a contiguous, exclusive 14-state-plus-DC territory serving roughly 60 million consumers. It is a manufacturing-and-distribution business, not a brand owner: it buys concentrate from KO, makes and packages finished beverages in 10 plants, and moves them to ~60 distribution centers and tens of thousands of retail outlets via a direct-store-delivery (DSD) network. FY2025 revenue was $7.23B.

The investment story of the last five years is a transformation in profitability. Following the 2013–2017 “System Transformation” — when COKE absorbed a large block of refranchised KO territory and quadrupled in size — the business spent years digesting and optimizing. That work has paid off: operating margin doubled from 6.3% (FY20) to 13.2% (FY25), gross margin rose from 35.3% to 39.7%, EBITDA margin from 9.8% to 16.2%, and net income tripled from $172M to $571M. Return on invested capital climbed from ~14% to ~25% — an exceptional figure for a capital-intensive bottler and the single fact that most distinguishes COKE from every other Coca-Cola bottler.

The market has noticed. The stock re-rated from ~7x EV/EBITDA in 2020 to ~14x today, compounding roughly 7-fold. On an own-history valuation basis, COKE’s price-to-sales sits at the 97th percentile of its ten-year range and the composite valuation at the 83rd — this is, on most measures, the most expensive the stock has ever been. It now trades level with developed-market peer Coca-Cola Europacific Partners (CCEP), ~65% above emerging-market peer Coca-Cola FEMSA (KOF), and — strikingly — at a higher EV/EBITDA than PepsiCo, despite carrying the lowest EBITDA margin in the bottler set.

The central analytical tension is how much of the margin transformation is durable. Roughly half is structural — territory maturation, automated DC consolidation, route density, and a richer product mix — and is genuinely KO-independent operating leverage. The other half is the post-COVID pricing wave layered on flat volume, and it is exposed to three forces working against it: (1) incidence-based concentrate pricing, which contractually returns a portion of COKE’s pricing gains to KO; (2) normalizing beverage-industry pricing as inflation fades; and (3) input-cost pressure (aluminum tariffs, freight, wages). Q1’26 showed the inflection — volume up, margin down.

Capital allocation has been a clear positive. In November 2025, COKE bought out The Coca-Cola Company’s entire ~18.8M-share equity stake for ~$2.4B (~$127/share post-split), funded with term debt — a clean related-party simplification (KO now owns zero COKE and gave up its board-designation right) executed at an accretive price. This, plus a 2024 modified-Dutch-auction tender and special dividend, drove book equity negative (−$740M) — a function of returning more than cumulative retained earnings, not of distress. Net debt/EBITDA is ~2.1x against ~$620M FCF; the balance sheet is sound. Governance is family-controlled: J. Frank Harrison III holds ~78% of the vote through super-voting Class B stock.

This memo takes no position and sets no price target. It frames COKE as a high-quality, structurally-capped franchise whose valuation now embeds continued margin expansion that the system’s own economics are designed to limit.

2. Business Overview

What the Company does. Coca-Cola Consolidated manufactures, markets, and distributes nonalcoholic ready-to-drink (NARTD) beverages — overwhelmingly the products of The Coca-Cola Company — within an exclusive, contractually-defined territory covering all or part of 14 states (concentrated in the Southeast and Mid-Atlantic, extending into the Midwest) plus the District of Columbia. It is the largest of KO’s roughly 65 U.S. bottlers, accounting for a high-teens percentage of all KO bottle/can volume sold in the United States. The Company operates ~10 manufacturing/production facilities and ~60 distribution/sales centers, serving an estimated 60 million people.

How it makes money. COKE earns the spread between the price at which it sells finished beverages to retailers and the cost to make and deliver them. Its largest cost is concentrate and syrup purchased from KO (and, for partner brands, from those brand owners). It packages concentrate with sweetener, water, CO₂, aluminum cans, PET bottles, and closures into finished product, then sells through three broad channels:

• Bottle/can (the core, ~85%+ of volume): packaged beverages sold to large retail (Walmart, Kroger, Costco, Target), convenience/gas, drug, mass, and small “up-and-down-the-street” outlets, delivered via DSD.
• Other/fountain (post-mix): fountain syrup sold to restaurants and foodservice that dispense finished drinks, plus dispensing equipment.
• Sales to other bottlers / National Product Supply: COKE manufactures certain products for, and sells to, other Coca-Cola bottlers under the National Product Supply Group (NPSG) — roughly $384M of intercompany-style revenue on which KO has price-setting authority.

Product mix. Revenue splits between Sparkling beverages (the trademark Coca-Cola brands, Sprite, Fanta, Dr Pepper — carbonated soft drinks) and Still beverages (water, sports drinks, energy, tea, coffee, juice, enhanced water, protein/dairy via fairlife). Sparkling remains the majority of volume and the profit engine; Still is the growth mix, led by energy (Monster, full distribution rights) and BODYARMOR. Roughly 85% of volume is KO-owned or KO-licensed brands; the balance is partner and Company-owned brands.

Recurring vs. non-recurring. Revenue is highly recurring and consumable — beverages are bought and re-bought continuously, with no contractual subscription but extremely stable repeat demand. There is no meaningful backlog or project revenue; the business is a high-velocity, low-ticket, repeat-purchase distribution machine. Seasonality is modest, with Q2–Q3 (warm months) the strongest quarters and Q1 the weakest.

History — the System Transformation. From 2013 to 2017, KO refranchised most of its company-owned U.S. bottling operations to independent bottlers; COKE was the largest acquirer, expanding its territory roughly four-fold and taking on the associated plants, routes, and — critically — the acquisition-related contingent consideration: a perpetual obligation to pay KO quarterly “sub-bottling” royalties on the distribution rights acquired. The decade since has been a story of integrating that footprint and extracting efficiency from it. The current high-margin, high-ROIC COKE is the matured output of that build.

Verdict: A simple, understandable, consumable-staple distribution business with exceptionally stable demand — but one whose economics are defined, top and bottom, by contracts with The Coca-Cola Company rather than by COKE’s own market power. The “what it does” is easy; the “who controls the economics” is the whole analysis.

3. Industry Dynamics

The three-layer Coca-Cola system. The U.S. NARTD market is dominated by three systems — Coca-Cola, PepsiCo, and Keurig Dr Pepper — each historically organized as a brand owner (concentrate manufacturer) sitting atop a layer of bottlers (manufacturing/distribution). The Coca-Cola system is the most explicitly split: KO owns the trademarks, sets brand strategy and marketing, manufactures concentrate at very high margin and near-zero capital intensity, and franchises exclusive geographic territories to bottlers who own all the plants, trucks, coolers, and working capital. The profit pool is deliberately and asymmetrically divided. KO’s North America segment earns ~26% operating margins and the broader company ~29% on ~4% capex/revenue; bottlers like COKE earn ~13% operating margins on ~4–5% capex/revenue but carry the entire asset base. The cleanest evidence of this design: KO’s own segment margins rise the further KO sits from owning bottling.

Volume and the secular backdrop. U.S. sparkling soft drink volume has been in slow secular decline for two decades on health/sugar concerns, only partly offset by zero-sugar reformulation and smaller pack sizes. The system’s revenue growth has therefore come from price/mix — higher realized price per case, premium packaging (mini-cans, multi-packs), and mix shift toward still, energy, and protein. Energy (Monster, and now KO’s broader energy push) and sports hydration (BODYARMOR, Powerade) are the growth categories; bottled water is high-volume/low-margin; juice and tea are mature. The category is defensive and non-cyclical — beverage consumption barely moves with GDP — which is why COKE loads negatively on the market beta factor and positively on low-volatility and dividend-yield factors.

Bottler economics and barriers. Bottling is capital-intensive (plants, fleet, cold-drink equipment), working-capital-heavy (inventory, receivables to large retailers), and scale-driven: the economics are won or lost on route density — cases delivered per stop, per mile, per labor hour. Within a given territory, the incumbent bottler with the densest network has a structural cost advantage no entrant can replicate, because a second DSD network across the same geography would carry duplicate fixed cost at half the volume. Barriers to entry are therefore very high within territory — but they are largely legal/contractual (the exclusive franchise, protected under the Soft Drink Interbrand Competition Act of 1980) rather than purely market-earned. The flip side: the bottler cannot grow by taking a competitor’s territory; it grows only with its existing geography’s consumption and with whatever pricing the system permits.

Where the profit sits — and the capital cycle. In Marathon “Capital Returns” terms, U.S. Coca-Cola bottling is a consolidated, mature, low-new-supply industry: there is no wave of new bottling capacity being built, refranchising is complete, and the major bottlers (COKE, plus regional players like Liberty, Swire, and Arca’s U.S. operations) hold stable, protected territories. That supply-side discipline is favorable and supports returns. But the same maturity means the demand side is low-growth, and the franchisor (KO) is structurally positioned — via concentrate pricing — to capture the incremental economics of any pricing the bottlers achieve.

Verdict: a structurally stable but structurally subordinate industry. Bottling is a good business to be the scaled incumbent in (high barriers, recurring demand, consolidated supply) but a permanently junior one (capital-heavy, margin-capped, price-constrained by the brand owner). It is a far better industry for KO than for KO’s bottlers. COKE is the best-positioned player in a structurally second-tier layer.

4. Competitive Position & Moat

Does COKE have a moat? Yes — but it is largely KO’s moat, sub-leased to COKE on KO’s terms, plus a genuine local cost advantage that is COKE’s own.

In Greenwald’s taxonomy, COKE holds three advantages, but their ownership differs sharply:

1. Demand-side captivity (rented). Consumers are captive to the brands — Coca-Cola, Sprite, Monster, Dr Pepper, BODYARMOR, fairlife. That captivity is real and powerful, but it belongs to the brand owners, not to COKE. COKE is the conduit; if the franchise were reassigned, the captivity would travel with the brands, not with Consolidated.

2. Local economies of scale + route density (owned — this is COKE’s real moat). Within its exclusive territory, COKE runs the densest DSD network: more cases over the same fixed routes, plants, and cold-equipment base than any conceivable second entrant could achieve. This is a genuine, durable, locally-bounded cost advantage that COKE itself created and maintains — and it is the mechanism behind the ~25% ROIC. It is the part of the moat that would not deteriorate if you stress-tested it, because no rational competitor would build a duplicate distribution network across COKE’s geography to serve half the volume at double the unit cost.

3. The exclusive territory franchise (granted, conditional, revocable-on-breach). The Comprehensive Beverage Agreement (CBA) grants COKE the exclusive right to distribute KO brands in its territory. This is the largest single barrier — but it is a license, not owned property. It carries minimum performance/capital covenants, KO approval rights over any change of control of COKE, and loss-of-rights provisions on default. It is durable in practice (KO has every incentive to keep a strong, well-capitalized bottler in place, and the relationship is decades deep and now even cleaner post the 2025 stake buyout) — but it is conditional, and its terms (concentrate price, sub-bottling fee, marketing support) are set by KO, not negotiated as between equals.

The incidence-pricing ceiling — pressure-testing the moat. The most important structural fact in the entire analysis is incidence-based concentrate pricing: KO’s concentrate price to COKE is set as a function of COKE’s own net realized pricing, channel, and package mix. In plain terms, when COKE raises retail prices, the concentrate it must buy from KO automatically becomes more expensive — KO claws back a contractually-defined slice of the very price increase COKE worked to achieve. This is the mechanism by which the system ensures the pricing power lives at KO. It does not eliminate COKE’s ability to profit from efficiency (route density, plant automation, mix — these are COKE’s to keep), but it specifically caps COKE’s ability to durably expand margin through price. Layered on top: KO can unilaterally set prices on COKE’s ~$384M of bottler-to-bottler (NPSG) sales, and ~$200M/year of KO marketing funding is discretionary and withdrawable, not contractual.

Customer concentration on the other side. Downstream, COKE’s largest customers — Walmart and Kroger together are roughly a third of volume — buy without long-term contracts and wield substantial buying power. So COKE is squeezed at both ends of its own value chain: KO upstream (concentrate, sub-bottling, marketing), big-box retail downstream (price).

Versus peers. COKE’s ROIC (~25%) is roughly double KOF’s (~10–12%) and CCEP’s (~11.5%) and ahead even of franchisor KO’s (~16–17%). That gap is the proof that COKE’s operational moat — territory density and post-2017 efficiency — is real and best-in-class among bottlers. But its EBITDA margin (~16%) is the lowest of the bottler set (KOF ~20%, CCEP ~19%, PEP ~22%), because COKE’s territory mix is more big-box/large-format (lower margin per case, higher volume) and because the U.S. incidence regime is tight. High ROIC on lower margin = a capital-efficiency story (asset turns, the leveraged recap shrinking the capital base), not a pricing-power story.

Verdict: a protected, utility-like franchise — durable but capped. COKE owns a genuine local cost moat and is the highest-return operator in its layer. But it rents its demand-side captivity from KO, holds its territory on a conditional license, and operates under a pricing system explicitly engineered to prevent it from keeping durable price-driven margin gains. Call it what it is: an excellent operator of a structurally capped franchise — not an autonomous pricing-power compounder.

5. Growth History and Forward Opportunities

The five-year record. Revenue compounded ~7.6%/year from $5.0B (FY20) to $7.23B (FY25). But the composition of that growth is the whole story:

The 2021–2022 double-digit growth was the post-COVID inflationary pricing wave; 2023–2025 decelerated to mid-single digits. Crucially, almost all of the recent growth is price/mix, not volume: FY24 net sales rose +3.7% on volume −0.6%, and FY25 rose +4.8% on volume of roughly +0.3%. Physical case volume has been flat to slightly down; the entire top line has been carried by higher realized price and favorable mix (still/energy, premium packaging). This is precisely the kind of growth that incidence pricing is designed to partially recapture and that normalizes as inflation fades.

Margin expansion — structural or cyclical? This is the key debate, and the honest answer is both, roughly half-and-half:

• Structural (durable, COKE’s own): the post-2017 territory finally running at scale — consolidation of warehouses into large automated distribution centers, route optimization, manufacturing-network rationalization, the “ARTM” (advanced route-to-market) and supply-chain investments, and a richer mix toward higher-velocity still/energy/protein products. These are real, repeatable, KO-independent operating-leverage gains that took gross margin from 35% to ~40% and should hold.
• Cyclical (borrowed, exposed): the incremental margin from pricing ahead of cost during 2021–2023, when COKE raised prices faster than concentrate/input costs rose and before incidence fully caught up. That lever is largely spent, and the mechanism now runs the other way.

Q1’26 — the live inflection. Q1’26 revenue rose +16.9% year-over-year to $1.85B and operating income +25% — a strong headline. But beneath it, volume finally inflected positive (+6.4% on an adjusted/comparable basis) while gross margin compressed ~70bps as tariff-driven aluminum costs (~$35M in the quarter) “outpaced our pricing actions,” compounded by a new front-line wage investment. This is the textbook signature of the growth mix flipping from high-margin price to lower-margin volume just as input costs bite — exactly what the structural/cyclical split predicts. One quarter is not a trend, but it is the most important recent data point and it cuts against the “margins keep climbing” extrapolation embedded in the multiple. (Note: the +16.9% headline partly reflects an easy Q1’25 comparison; treat the volume +6.4% / gross-margin −70bps as the cleaner read.)

Forward opportunities. (1) Still/energy/protein mix — continued shift toward Monster, BODYARMOR, fairlife, and zero-sugar sparkling supports price/mix without volume growth. (2) Capacity and automation — ongoing investment in production and DC capacity (capex ~4–5% of revenue) extends the density advantage. (3) Digital/immersive ordering — B2B ordering platforms and route productivity. (4) Operating leverage on flat volume — if structural efficiency keeps compounding, margins can grind higher even without unit growth. What COKE cannot do is meaningfully grow its addressable market: the territory is fixed, U.S. sparkling volume is flat-to-declining, and pricing is incidence-capped.

Verdict: medium-quality growth. The structural efficiency gains are high-quality and durable; the pricing-driven portion is lower-quality and cyclically exposed. Volume growth is structurally absent. This is a flat-to-low-volume, price/mix-and-efficiency story — fine for a defensive compounder, but not the high-quality unit-growth engine a ~14x EBITDA multiple typically implies.

6. Financial Quality

Revenue and margins. Covered above: ~7.6% five-year revenue CAGR, gross margin ~40%, operating margin ~13%, EBITDA margin ~16% — all near multi-decade highs. The trajectory is impressive but plateauing (FY24→FY25 operating margin essentially flat at ~13.2–13.3%), consistent with the structural gains maturing and the cyclical pricing lever fading.

Quality of earnings — the contingent-consideration distortion. The single most important QoE item is non-cash and non-operating: the fair-value remeasurement of the acquisition-related contingent consideration liability (the present value of perpetual sub-bottling payments owed to KO/CCR on the System Transformation distribution rights). This liability totaled $717.9M at 12/31/25, and its mark-to-market — driven mainly by changes in COKE’s WACC/discount rate and cash-flow projections — runs through the income statement as a charge or credit:

• FY25: a $131.9M charge (increase in the liability, primarily a lower discount rate)
• FY24: a $59.2M charge
• FY23: a $159.4M charge (plus a one-time $112.8M pension settlement charge that year)

This is the mechanical reason FY25 net income ($571M) came in below FY24 ($633M) despite FY25 operating income being higher ($951M vs $920M): below the operating line, FY25 absorbed ~$41M more interest expense (the recap) and ~$73M more contingent-consideration charge. Normalize this out. GAAP net income and GAAP P/E are distorted and volatile; the clean signals are operating income, EBITDA, and free cash flow. On those, FY25 was the strongest year on record.

Run-rate earnings. With the November 2025 buyout retiring 18.8M shares, the share count dropped to ~66.6M, but FY25’s weighted-average diluted count (~83.8M Common + the constant ~10M Class B under the two-class method = ~93.9M) still reflects mostly the pre-buyout base. The cleaner forward read is diluted EPS on the post-recap ~66.6M-share count: Q1’26 delivered $1.67 (seasonally weakest quarter), implying a meaningfully higher full-year run-rate as Q2–Q3 seasonality kicks in. (The basic-vs-diluted “gap” some screens flag is not an anomaly or a hidden convertible — it is simply the two-class method assuming 100% conversion of the ~10M Class B shares into Common for the diluted figure.)

Free cash flow. FY25 operating cash flow was $932M; capex $312M (down from $371M in FY24); free cash flow ~$620M. Capex runs ~4–5% of revenue — light for a “capital-intensive” bottler, reflecting that the heavy System-Transformation build is behind it. Cash conversion is favorable: the cash conversion cycle is ~27 days, helped by fast inventory turns and large-retailer payment terms. Aggregated “FCF” figures swing on working-capital and investment-portfolio timing; the maintainable owner-FCF is best anchored at roughly $550–650M, or ~$8–10/share.

Returns on capital. ROIC ~25% (FY25), up from ~14% (FY20). This is the headline quality metric and it is genuine — but note two amplifiers: (1) the denominator shrank as the leveraged recap reduced invested equity capital, and (2) ROE is unusable (equity is negative). The 25% ROIC is real economic productivity, but a portion of its recent increase is financial-structure-driven, not purely operational.

Balance sheet and leverage. Total debt rose to ~$2.79B (from ~$1.79B) to fund the KO buyout; cash $282M; net debt ~$2.5B; net debt/EBITDA ~2.1x (~2.25x including leases). Book equity is negative (−$740M) — entirely a consequence of returning more than cumulative retained earnings via buybacks and specials, not a sign of distress. P/B is meaningless here (hence the null in screens) and ROE is not a usable metric; ROIC and EV/EBITDA are the correct lenses. Interest coverage was ~22x on FY25’s reported interest ($43M), but that understates the run-rate: Q1’26 interest of $32M annualizes to ~$128M, cutting coverage to a still-comfortable ~7–8x. Roughly 43% of the debt stack is floating-rate (term loans), introducing modest rate sensitivity. Pension is modestly underfunded but de-risked after the 2023 settlement. Liquidity (cash + revolver) is ample against ~$620M annual FCF.

Verdict: high-quality economics, with the quality concentrated in cash generation and capital efficiency rather than reported GAAP earnings. The business does improve with scale (the ROIC and margin trajectory prove it), the cash conversion is excellent, and the balance sheet — though optically alarming on book equity — is sound at ~2x leverage. The two cautions: GAAP net income is distorted by the contingent-consideration mark (normalize to EBIT/EBITDA/FCF), and part of the recent ROIC lift is leverage-engineered.

7. Capital Allocation

The headline events. COKE’s capital allocation over the last two years has been aggressive, shareholder-friendly, and — in my read — intelligent:

• 2024 modified Dutch-auction tender (~$626M) plus a large special dividend (~$16/share pre-split), returning excess cash built up through the high-FCF years.
• November 2025 buyout of The Coca-Cola Company’s entire equity stake — ~18.84M Common shares (held via KO subsidiary Carolina Coca-Cola Bottling Investments) for ~$2.4B (~$127/share post-split), plus ~$212M of open-market repurchases, for ~$2.6B total in FY25. This is the standout move. It was financed with a $1.2B bridge, termed out in December 2025 into ~$1.35B of variable-rate term loans (3-year and 5-year tranches). KO now owns zero COKE shares and relinquished its board-designation right — a clean simplification of the most important relationship in the business, executed at a price (~$127) well below where the stock trades today (~$188), i.e., highly accretive in hindsight.

Is the leverage prudent? Yes. Pro-forma net debt/EBITDA of ~2.1x against a business generating ~$620M FCF on light capex, with extraordinarily stable defensive demand, is conservative-to-moderate — not aggressive. The interest run-rate (~$128M) is covered ~7–8x by EBIT. This is value-accretive financial engineering on a cash machine, not balance-sheet recklessness. The main caveats are governance-flavored: the KO-stake price was negotiated (a related-party transaction, no competitive minority tender for those specific shares), and ~43% of the debt is floating.

Dividends. COKE was historically a miserly dividend payer — the quarterly dividend sat frozen at $0.25/share (pre-split, i.e., ~$1.00/year on a stock that ran from $100 to >$1,000) for many years, an anomaly for a Dividend-aristocrat-adjacent staple. Management has recently begun raising it (FY25 declared ~$1.04/share post-split; payout ratio ~15%), but the yield is still only ~0.5–0.6% — very low for a consumer staple. The capital-return preference is clearly buybacks/specials over a growing regular dividend.

M&A and reinvestment. M&A has been minor since the System Transformation (small bolt-ons, ~$15–20M/year). The reinvestment story is internal: capex into automated DCs, production capacity, fleet, and cold-drink equipment at ~4–5% of revenue — disciplined and returning ~25% ROIC. R&D is not a meaningful line (COKE is a distributor, not a product developer; innovation sits at KO).

Incentives and governance alignment. The proxy shows management compensated on absolute EBIT, free cash flow, and revenue (annual bonus) and EBIT/FCF/EBIT-margin (long-term performance plan) — no per-share or ROIC metric. This cuts two ways: the leveraged buyback does not mechanically inflate incentive payouts (a genuine positive — management isn’t being paid to financial-engineer EPS), but there is also no explicit per-share or return-on-capital alignment in the comp design. FY25 bonus paid at ~137% of target. Related-party density is high (KO concentrate purchases ~$2.26B, sub-bottling payments, manufacturing cooperatives, and a Harrison-family HQ lease), but all routine and disclosed. A minor internal-controls note: following CFO Scott Anthony’s March 2025 retirement, the Chief Accounting Officer (Matthew Blickley) was promoted to CFO while retaining the CAO title — combined roles worth monitoring.

Insider behavior. The Form 4 record (2024–25) shows: The Coca-Cola Company’s two code-S sales (the 2024 tender and the 2025 full exit); Vice Chair Everett Morgan Harrison’s modest open-market code-P purchase in May 2024 (a rare, mildly bullish discretionary buy) followed by a code-S sale in 2025; and Chairman/CEO J. Frank Harrison III’s transactions all code-J (trust/estate/gift transfers tied to the split), with no open-market activity. This is a routine controlled-company pattern with no broad insider distribution — the family is a long-term steward, not a seller.

Verdict: management has allocated capital intelligently. The KO-stake buyout was a genuinely good, accretive, simplifying transaction; leverage is prudent; reinvestment earns high returns; and incentives, while lacking per-share alignment, are not gamed by the recap. The one critique is the chronically stingy dividend relative to the cash generation — though buybacks at the prices paid have proven the better choice. This is a well-stewarded balance sheet.

8. Changes and Headwinds — Last Two Years

Strategic / capital-structure changes:

• 10-for-1 stock split, effective ~May 2025 — improving liquidity/accessibility of a stock that had run past $1,000; cosmetic but signals confidence and broadens the holder base.
• November 2025 buyout of KO’s entire stake — the most consequential change: KO exits the cap table, COKE levers up ~2x, book equity goes negative. Cleans up the central related-party relationship.
• 2024 Dutch-auction tender + special dividend — large capital return.
• CFO transition (March 2025) — Scott Anthony retired; CAO Matthew Blickley promoted to CFO (retaining CAO).

Operating developments:

• Margin plateau and Q1’26 inflection — operating margin flat at ~13% FY24→FY25; Q1’26 showed volume up +6.4% but gross margin down ~70bps on aluminum tariffs (~$35M) and a front-line wage investment. The cost cycle is turning.
• Aluminum/tariff exposure — 2025–26 tariff actions raised aluminum (can) costs materially; freight and labor also pressuring. COKE loads negatively on the oil-price factor (PET resin, freight). This is the most concrete near-term headwind.
• Continued mix shift to still/energy/protein (Monster, BODYARMOR, fairlife) supporting price/mix.

Industry/regulatory:

• GLP-1 / health overhang — the multi-year debate over whether GLP-1 weight-loss drugs and renewed sugar scrutiny pressure NARTD volume. So far volume has held (the system has reformulated and shifted to zero-sugar/smaller packs), but it is a live secular question for any beverage name.
• No COKE-specific litigation or regulatory event of note in the window.

Communication: COKE remains unusual in that it holds no quarterly earnings conference calls and issues no guidance — management communicates only through press releases and SEC filings. This reduces information flow, can increase volatility around prints, and is itself a (mild) governance/transparency consideration.

Verdict: On balance the changes strengthen the long-term structure (KO-relationship simplification, capital discipline, split) but introduce near-term risk (higher leverage, floating-rate exposure, turning cost cycle). The Q1’26 margin compression is the development most directly at odds with the bullish margin-extrapolation thesis.

9. Risk Analysis

Catastrophic-loss risk: Low. The realistic worst-case is a multiple de-rate plus margin normalization (a 30–40% drawdown — within its historical range; lifetime max drawdown −52%), not a permanent impairment. A true total loss would require the KO franchise to be revoked, which is remote given KO’s incentives and the relationship’s depth. The asymmetric tail risk is the franchise terms, not the balance sheet.

10. Valuation Discussion — Embedded Expectations

Where it trades. At ~$188, COKE carries a market cap of ~$12.5B and EV of ~$15.0–15.5B (incl. ~$2.5B net debt). On FY25 figures: EV/EBITDA ~13.2x (rising toward ~14x on current price), EV/Sales ~2.1x, P/E ~22–26x (distorted by the contingent-consideration charge), P/FCF ~20x on current price. On an own-history basis: P/S at the 97th percentile, P/E at the 69th, composite at the 83rd — the richest the stock has been on sales in its ten-year history.

Peer context:

The table frames the debate precisely. COKE trades at the developed-bottler ceiling — level with CCEP, ~65% above EM-bottler KOF, and above diversified PepsiCo — despite the lowest EBITDA margin in the bottler set and the lowest dividend yield. The one fact that justifies the premium is ROIC ~25%, roughly double the other bottlers’ and ahead of franchisor KO’s. The bull case is “pay up for the highest-return bottler, converging toward franchisor quality”; the bear case is “a flat-volume, capital-heavy, margin-capped distributor with negative book equity and a 0.5% yield should not trade richer than PepsiCo.”

Embedded-expectations analysis — what must be true at ~$188? Reverse-engineering the multiple: at ~14x EV/EBITDA on a business with ~flat volume and incidence-capped pricing, the market is underwriting (1) that the ~16% EBITDA margin is a durable floor and grinds higher (the structural-efficiency thesis wins decisively over the cyclical-normalization risk), (2) that buybacks continue to shrink the share count and compound per-share FCF, and (3) that the franchise quality warrants a permanent re-rating to the developed-bottler/near-franchisor band. In short, the price assumes the structural half of the margin story dominates and the cyclical/incidence half does not bite. Q1’26 (volume up, margin down) is the first real-time test of that assumption — and it leaned the wrong way.

Scenario sketch (illustrative, not a target):

• Bear (~$130–150): margin normalizes toward 11% as incidence + costs bite; multiple de-rates to ~10–11x EV/EBITDA (the 2024 level). ~20–30% downside. The historically-normal outcome if the cyclical thesis wins.
• Base (~$180–200): margins hold ~13%, low-single-digit revenue growth, buybacks continue; multiple holds ~13–14x. Roughly flat-to-modestly-up — a fairly-valued compounder marking time.
• Bull (~$230–260): structural efficiency keeps grinding margins toward 15%+, volume growth sustains, multiple holds or expands toward KO-like quality. ~20–35% upside — requires the optimistic margin extrapolation to be right.

Verdict: COKE is fairly-to-fully valued. The valuation embeds the optimistic resolution of the margin debate. There is no obvious margin of safety at ~$188; the risk/reward is more symmetric-to-negative than the quality of the business suggests, because the quality is already in the price. The attractive entry is a de-rating toward the ~10–11x EV/EBITDA band (~$140–165) that the stock last saw 12–18 months ago.

11. Variant Perception

Consensus belief. COKE is a best-in-class, high-ROIC Coca-Cola bottler that has structurally transformed its profitability, is run by a disciplined family steward that just executed a brilliant buyout of KO’s stake, and deserves its re-rating toward franchisor-like quality. The factor tape supports the “owned quality” read: a low-beta (β≈0.5), low-volatility, dividend-tilted defensive that compounded ~34%/year over five years with a Sharpe above 0.8.

Strongest bull case. A uniquely high-return bottler (ROIC ~25%, double its peers) whose post-2017 territory density is a durable, widening local cost moat; whose efficiency program keeps compounding operating leverage on a defensively-stable revenue base; whose capital allocation (KO buyout, buybacks, low capex) compounds per-share value; and whose recent volume inflection (+6.4% in Q1’26) shows the growth engine re-accelerating. In this view, 14x EBITDA is reasonable for franchisor-adjacent quality, and the multiple holds or expands.

Strongest bear case. A capital-heavy, flat-volume U.S. distributor whose margin surge was bought with post-COVID pricing (volume −0.6%/+0.3% the last two years) that incidence pricing is specifically engineered to recapture; trading at its richest-ever P/S (97th percentile), above PepsiCo, on the lowest EBITDA margin in its peer set, with a 0.5% yield, negative book equity, and a turning cost cycle (Q1’26 gross margin −70bps on aluminum tariffs). In this view, the easy re-rating is over, the cyclical margin lever reverses, and the stock de-rates 20–30% toward its 2024 multiple.

The 3–5 assumptions that matter most:

1. Is the ~16% EBITDA margin a durable floor or a cyclical peak? (The whole thesis.) Falsified bearish by 2–3 quarters of operating-margin compression below ~12%; confirmed bullish by margins holding ~13%+ through the current cost cycle on volume-led growth.
2. How much does incidence pricing actually claw back? The FY22–25 concentrate-cost/incidence-rate trajectory is not cleanly disclosed; if concentrate cost is rising as a share of revenue faster than pricing, the cap is biting. (Key open question.)
3. Does the multiple hold? A staple bottler at 14x EBITDA above PEP is historically anomalous; mean-reversion of the multiple is the largest single swing factor, independent of fundamentals.
4. Volume — inflection or blip? Q1’26’s +6.4% must persist to validate the growth story; if it fades back to flat, the bear thesis strengthens.

The factor-positioning read. This is not a momentum trade and not a falling knife. The 12-month momentum factor loading has been neutralized (~0) after a +72% year, and the stock is in a modest ~12% quarterly pullback (m3 −39.7% annualized de-annualizes to roughly −12%) — a low-beta defensive that ran too far and is consolidating, not breaking. The negative beta-factor loading (−0.48) and positive dividend-yield/low-vol tilts mark it as an “owned quality” defensive whose crowd is long for safety and compounding, not chasing momentum. That positioning suggests the risk is de-rating from richness, not a momentum unwind — consensus is offsides on the durability of margins and the multiple, not on the direction of the tape. The variant view: the market has priced the structural-efficiency story as near-certain and is under-weighting the incidence-pricing ceiling and the cyclical half of the margin gain.

12. Fact vs. Interpretation Table

13. Open Questions

1. What is the actual FY22–25 trajectory of concentrate cost / incidence rate as a % of revenue? This is the quantitative key to sizing the incidence claw-back and the durability of margins. Not cleanly disclosed; the most important missing datum.
2. How much of the ROIC increase is operational vs. denominator-shrinking (leverage/buyback)? Decompose the 14%→25% ROIC into margin, asset-turn, and capital-structure effects.
3. What are the precise terms, coupons, maturities, and covenants of the new term loans, and the floating-rate sensitivity to a +100bps rate move?
4. Is the Q1’26 volume inflection (+6.4%) sustainable, or a comparison/timing artifact against an easy Q1’25?
5. What is the long-term CEO succession plan beyond J. Frank Harrison III, and does the family intend to retain control indefinitely?
6. How durable is KO’s discretionary ~$200M/year marketing funding, and what happens to COKE economics if KO reduces it?
7. GLP-1 / sugar-regulation sensitivity: what is the realistic volume elasticity for COKE’s sparkling mix over 5–10 years?

14. What Must Be True (Bull and Bear, with Falsification Tests)

Bull case — what must be true:

• The ~16% EBITDA margin is a durable structural floor that grinds higher on efficiency, not a cyclical pricing peak.
• Volume-led growth (Q1’26’s +6.4%) persists and can be delivered without surrendering gross margin.
• Incidence pricing and input costs do not materially compress operating margin from here.
• The multiple holds at ~13–14x EBITDA (franchisor-adjacent quality is permanent).
• Buybacks continue to compound per-share FCF.

Falsification test: Two consecutive quarters of operating-margin compression below ~12% with concentrate cost rising as a share of revenue — would prove the cyclical/incidence thesis is winning and break the “durable margin expansion” bull case.

Bear case — what must be true:

• The recent margin surge was substantially cyclical (post-COVID pricing on flat volume) and reverses as incidence claws back price and input costs rise.
• The multiple mean-reverts from its richest-ever level toward the ~10–11x EBITDA band as the re-rating exhausts.
• U.S. sparkling volume stays flat-to-declining, leaving no growth engine but price/mix.

Falsification test: Four+ quarters of operating margin holding or expanding above 13% on positive volume and the EV/EBITDA multiple sustaining ≥13x — would prove the structural-quality thesis is durable and break the “cyclical peak / de-rating” bear case.

15. Source Appendix

See Appendix B for the full primary-source list. Principal sources: COKE FY2025 Form 10-K (filed 2026-02-18); Q1’26 Form 10-Q (filed 2026-05-06); FY2026 DEF 14A proxy (2026-03-23); FY2025 8-K earnings release (2026-02-18) and Q1’26 release (2026-05-06); SEC Form 4 filings (2024–2025); aggregated fundamentals and ratios (accessed 2026-06-14); own-history valuation percentiles and price history; an empirical factor-loading and risk-adjusted-return model; and prior peer reports on KOF (2026-06-08), KO (2026-06-11), PEP (2026-06-11), and MNST (2026-06-13) for peer cross-read.

This note contains no buy/sell recommendation and no price target. The single labeled exception is the “Claude’s Take” block at the top, which is explicitly the author’s own subjective view. All other sections discuss valuation only as embedded expectations and scenarios.

APPENDIX A — Standard Diligence Questionnaire

Coca-Cola Consolidated, Inc. (NASDAQ: COKE) — Report date 2026-06-14

Supplemental to the research memo. Fact / Interpretation / Assumption labels applied where it matters.

General

What thoughtful questions have other investors asked about this company? The dominant question is durability of the margin transformation: is the doubling of operating margin (6%→13%) a permanent structural step-change or a post-COVID pricing peak that incidence pricing and cost inflation will erode? Secondary questions: How should one value a bottler with negative book equity and ROE? (Answer: ROIC and EV/EBITDA, not P/B/ROE.) Why does COKE trade above PepsiCo on EV/EBITDA? Is the chronically low dividend a capital-allocation flaw or a feature? And how should minority holders weigh the 78%-vote family control? The lack of earnings calls/guidance means these debates are conducted with less management input than for most large caps.

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Interpretation: A cyclical-to-structural high. Margins are at multi-decade peaks; ROIC ~25% is near a record. Roughly half the gain is durable (efficiency), half cyclical (pricing on flat volume) — so earnings quality is high but the margin is more likely near a ceiling than a floor.

Driven by external environment or internal actions? Both. Internal: post-2017 territory integration, automated DCs, route density, mix. External: post-COVID inflationary pricing power across the beverage industry. The internal portion is durable; the external portion is fading.

How stable are revenues? Fact: Very stable — consumable staple, repeat-purchase, defensively non-cyclical (negative market-beta and beta-factor loadings, β≈0.5). Revenue barely moves with GDP; the risk is slow secular volume decline, not cyclical collapse.

Outlook for products/services? Flat-to-low volume on sparkling (secular decline partly offset by zero-sugar/small-pack); growth in still/energy/protein mix (Monster, BODYARMOR, fairlife). Top-line growth is a price/mix-and-efficiency story, not a unit-growth story.

How big is the market — growing or shrinking? Fact: COKE’s addressable market is fixed by its exclusive territory (14 states + DC, ~60M consumers). It cannot expand geographically (territory is protected/granted). U.S. NARTD value grows low-single-digits on price/mix; sparkling volume is flat-to-declining. Domestic only — no international exposure.

Business Quality & Competitive Moat

Is the industry getting more or less competitive? Stable. Bottling territories are consolidated and protected; there is no new-entry threat within territory. Competition is brand-vs-brand (KO vs PEP vs KDP) at the shelf, fought largely by the brand owners, not a bottler-vs-bottler war.

How profitable is the business (ROIC, ROE)? Fact: ROIC ~25% (FY25), exceptional for a bottler and roughly double KOF/CCEP. ROE is not usable (negative equity). Operating margin ~13%, EBITDA margin ~16% (lowest in the bottler peer set, reflecting big-box-heavy mix). High ROIC on modest margin = a capital-efficiency story.

How profitable is the industry — competitors, barriers? The bottling layer is modestly profitable (~13% operating margins) and capital-heavy; the franchisor layer (KO) is highly profitable (~29% margins, ~4% capex). Barriers to entry within territory are very high but legal/contractual (exclusive franchise under the Soft Drink Interbrand Competition Act) plus local route-density scale. Few competitors per territory (one dominant bottler each).

Can the business be easily understood? Yes — buy concentrate, make and deliver beverages, earn the spread. The complexity is in the contracts with KO (CBA, incidence pricing, sub-bottling fee), not the operations.

Can it be undermined by foreign low-cost labor? No — it is a domestic, perishable, heavy, low-value-density physical-distribution business. Route-to-market cannot be offshored.

Do brands matter? Critically — but the brands belong to KO, not COKE. COKE rents brand captivity; it does not own it. This is the central moat caveat.

What is the nature of competition? At the consumer level, brand competition (Coke vs Pepsi). At COKE’s level, no direct competition for its franchise — territory is exclusive. COKE competes only to win shelf space and execution against the Pepsi/KDP systems within its geography.

Customers’ switching costs? Low for large retailers (no long-term contracts; Walmart/Kroger ~⅓ of volume wield buying power), but they cannot switch suppliers of Coca-Cola products — only COKE distributes KO brands in-territory. So retailers have price leverage but not source leverage on KO brands.

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? Interpretation: Yes — the exclusive territory franchise/distribution rights and the route-density network are worth far more than carried (intangibles ~$0.94B, goodwill ~$0.17B). The economic value of the franchise is the gap between ~$15B EV and ~$2.9B net tangible assets.

Off-balance-sheet liabilities? The major contingent item — the perpetual sub-bottling obligation to KO — is recognized, as the $717.9M acquisition-related contingent consideration liability (PV of future payments). Operating leases are on balance sheet. Pension is modestly underfunded (de-risked post-2023 settlement). No major hidden liabilities identified.

How conservative is the accounting? Mixed. Conservative in cash terms (clean FCF, modest capex). Less so in GAAP earnings: the contingent-consideration mark-to-market ($132M FY25 charge) introduces large non-cash, discount-rate-driven swings that obscure operating trends — normalize to EBIT/EBITDA/FCF.

How CapEx-hungry is the business? Fact: Moderate-to-light now — capex ~4–5% of revenue (~$312M FY25), down from the System-Transformation build. Lighter than the “capital-intensive bottler” reputation, which is why FCF conversion and ROIC are strong.

Capital Allocation & Management

How much FCF, and how is it used? Fact: ~$620M FCF (FY25). Used overwhelmingly for buybacks and special dividends (the ~$2.6B FY25 KO-stake buyout + 2024 tender/special), modest regular dividend (~$87M), minimal M&A. Philosophy: return excess cash via buybacks/specials; keep the regular dividend low.

Significant acquisitions recently? Only the buyback of KO’s equity stake (not an operating acquisition). Operating M&A is minor (~$15–20M/year bolt-ons). The transformative M&A (System Transformation) was 2013–2017.

Buying back shares? Aggressively — shares fell from 93.7M (FY23) to 66.6M (FY25), ~29% reduction, via the 2024 tender and 2025 KO buyout, the latter at an accretive ~$127 vs ~$188 now.

Issuing shares to insiders? No meaningful dilution; SBC is immaterial. Insider share changes are trust/estate transfers (code-J), not new issuance.

Compensation policy? Fact: Incentives on absolute EBIT/FCF/Revenue (annual) and EBIT/FCF/EBIT-margin (long-term) — no per-share or ROIC metric. Positive: the leveraged buyback doesn’t game payouts. Negative: no explicit per-share/return-on-capital alignment. FY25 bonus ~137% of target.

Motivations of management? Family stewardship — J. Frank Harrison III (Chairman/CEO) controls ~78% of the vote via Class B; the family did not sell in the recap (only KO did). Long-term-owner orientation; low risk of value-destructive empire-building, but minority holders have no governance recourse.

Valuation & Market Data

ADR, MLP, or K-1 issuer? No — a standard U.S. C-corp common stock (NASDAQ: COKE). No K-1.

Dividend policy? Low and historically frozen (long stuck at $0.25/qtr pre-split); recently rising but yield only ~0.5–0.6%. Payout ~15%. Capital return is buyback-led, not dividend-led.

How profitable? Highly, on capital — ROIC ~25%; on margin, modestly — operating margin ~13%.

Is net income diverging from cash from operations? Fact: Yes — favorably. OCF ($932M FY25) substantially exceeds net income ($571M), because the $132M contingent-consideration charge and D&A are non-cash. Cash earnings exceed GAAP earnings — a positive quality signal once normalized.

Risks & Downside

What would cause the stock to decline? Margin normalization (incidence claw-back + input costs), a multiple de-rate from its richest-ever level, a volume disappointment, or a rate-driven interest-cost step-up. The most likely drawdown driver is valuation de-rating plus margin reversion, not a fundamental break.

Risk of catastrophic loss? Low. Worst realistic case is a 30–40% drawdown (within historical range; lifetime max DD −52%). True catastrophe requires KO franchise revocation — remote given KO’s incentives.

Chance of a total loss? Negligible — a profitable, cash-generative, franchise-protected staple at ~2x leverage. Total loss is not a credible scenario.

Recent News & Events

Has the business environment changed recently? Fact: Yes — (1) Q1’26 cost inflection (aluminum tariffs ~$35M, wages) compressing gross margin even as volume rose +6.4%; (2) the Nov-2025 KO-stake buyout reshaping the cap table and balance sheet (negative equity, ~2x leverage); (3) the May-2025 10:1 split; (4) March-2025 CFO transition. The cost cycle turning is the most thesis-relevant change.

Significant acquisitions? The KO-stake buyback (capital action, not operating M&A).

Change in accounting policies? None material; the contingent-consideration remeasurement is an ongoing (not new) policy.

Recent changes — markets, facilities, management? Continued automated-DC/capacity investment; CFO change (Blickley, retaining CAO role); no new territories (territory is fixed). COKE continues its no-earnings-call practice.

APPENDIX B — Source Appendix

Coca-Cola Consolidated, Inc. (NASDAQ: COKE) — Report date 2026-06-14

Primary sources prioritized over secondary; every material claim in the memo traces to one of the below. Facts distinguished from interpretation in the memo body.

Primary — SEC filings (US filer, CIK 0000317540)

Mirrored locally to output/COKE/sources/ from SEC EDGAR; trailing 60 months. Read in place.

1. Form 10-K, FY2025 — filed 2026-02-18 (coke-20251231.htm). PRIMARY source for business description, territory footprint, the Comprehensive Beverage Agreement (CBA) and incidence-based concentrate pricing, risk factors, MD&A, the acquisition-related contingent consideration liability ($717.9M; $131.9M FY25 fair-value charge), segment/volume disclosure, debt, negative stockholders’ equity, two-class EPS method, and the KO-stake repurchase.
2. Form 10-K, FY2020–FY2024 — filed 2021–2025 (coke-2020…–coke-2024…). Multi-year financial trend (revenue, margin, ROIC, capex, dividends, buybacks).
3. Form 10-Q, Q1’26 — filed 2026-05-06 (coke-20260403.htm). Q1’26 revenue +16.9% YoY, volume +6.4%, gross-margin −70bps, aluminum-tariff (~$35M) and wage commentary, post-recap share count (~66.6M), run-rate interest expense.
4. Form 10-Q, FY2024–FY2025 quarters — quarterly progression of margins, volume, debt, buyback.
5. DEF 14A proxy, 2026 — filed 2026-03-23 (coke-20260323.htm). Executive compensation and incentive metrics (absolute EBIT/FCF/Revenue; no per-share/ROIC metric), Harrison-family Class B control (~78% vote), related-party transactions (KO concentrate ~$2.26B, sub-bottling, cooperatives, HQ lease), controlled-company governance, CFO transition.
6. DEF 14A proxies, 2022–2025 — comp/governance trend.
7. Form 8-K — FY2025 earnings release (2026-02-18); Q1’26 earnings release (2026-05-06); 2025 debt/term-loan and tender/recap-related 8-Ks; dividend declarations; 10-for-1 split. ~44 8-Ks in the corpus.
8. Schedule TO-I / SC filings — 2024 modified-Dutch-auction tender offer documentation (~25 SC filings in corpus).
9. Form 3 / Form 4 (insider) — 2024–2025: The Coca-Cola Company code-S sales (2024-07-05 tender; 2025-11-10 full stake exit); Vice Chair Everett Morgan Harrison code-P open-market purchase (May 2024) and code-S (Sep 2025); J. Frank Harrison III code-J trust/estate transfers. Pulled directly from EDGAR (bodies not all mirrored).

Primary — quantitative data sources

10. Aggregated fundamentals data (accessed 2026-06-14) — income statement, balance sheet, cash flow, profitability ratios (ROIC, ROA, margins), enterprise value, valuation multiples, per-share data (annual FY2020–FY2025 + quarterly through Q1’26), reconciled to the 10-K. Note: COKE does not host quarterly earnings conference calls, so no call transcripts exist.
11. Own-history valuation percentiles (2026-06-12) — P/S 97th, P/E 69th, composite 83rd percentile of the stock’s ten-year range; P/B not meaningful (negative book equity).
12. Price history — split/dividend-adjusted OHLCV; price $187.89 (2026-06-12).
13. Empirical factor model (accessed 2026-06-14) — factor betas (Market 0.53; BetaFactor −0.48; DividendYield +0.24; OilPrice −0.12; Momentum ~0; Consumer Staples +0.34); risk-adjusted returns (y5 +34%/yr, y1 +72%, m3 −39.7% annualized; lifetime max DD −52%); idiosyncratic vol ~34%; factor-similar peers (TAP, CCEP, MNST, KHC, SYY).

Secondary — peer cross-read

14. Peer public filings — Coca-Cola FEMSA (KOF), The Coca-Cola Company (KO), PepsiCo (PEP), Monster Beverage (MNST), and Coca-Cola Europacific Partners (CCEP) annual/interim reports — for peer valuation multiples, bottler-vs-franchisor economics, incidence-pricing mechanics, and industry/volume framing.

Secondary — external context

15. CCEP (Coca-Cola Europacific Partners) FY2025 results — developed-market KO-bottler comp (EV/EBITDA, margin, ROIC, leverage) for the peer table.
16. General financial press / company IR for confirmation of the 10:1 split timing (~May 2025), the 2025 KO-stake buyout headline terms, and COKE’s no-earnings-call practice.

Notes on data reconciliation

• Aggregated third-party data is used for speed; the FY2025 10-K is primary. Where they differ on a material number, the filing governs. Aggregated “FCF” variants swing on working-capital/investment-portfolio classification — maintainable owner-FCF anchored at ~$550–650M.
• GAAP net income is distorted by the non-cash contingent-consideration mark; the memo normalizes to EBIT/EBITDA/FCF.
• ROE and P/B are not usable (negative book equity); ROIC and EV/EBITDA are the correct metrics.